Johnson & Johnson JNJ

$278.70 -3.85 (-1.36%)

Valuation

Market cap
680,185,472,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.83
P/E (forward)
25.70
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,979,200
Avg volume
7,332,246
Day's range
$277.56 – $281.72
Shares out
2,407,310,000
Stochastic %K
53%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

superalby Nov 18, 5:26 AM
$BDTX management now have to focus about partnership. ​A partner isn’t just about non-dilutive cash—a Big Pharma's global oncology network can save 6–12 months off enrolling the 400-patient Phase 3 trial for #silevertinib. No dilution risk, faster clinical readouts ​With a massive patent cliff looming, Big Pharma needs high-potential oncology assets to replenish their pipelines. Silevertinib is exactly the kind of next-gen breakthrough they are looking for! $MRK $AZN $JNJ $BMY
1 replies
CrazyCajun7 Nov 18, 5:24 AM
$SLS who's there? $JNJ $MRK
0 replies
RyGuy79 Nov 18, 5:13 AM
$MRK trending more than $JNJ because of $SLS. This suitor makes the most sense.
0 replies
shopno Nov 18, 1:01 AM
$SLS I was thinking of the same and then recall Stergiou mentioned it in an investor conversation couple of months ago indicating that GPS at CR2 mOS >= Onureg at CR1 mOS, which means $SLS will file sBLA for CR1 approval after CR2z The reality of course will be that $SLS doesn’t need to go with filing the BLA / sBLA at all! $JNJ and $MRK have already started their homeworks without a doubt. Exciting time ahead!
0 replies
TheDailyBuyout Nov 17, 11:58 PM
$JNJ J&J to buy eye-disease biotech Ollin for $2.2B upfront. The deal gives J&J a late-stage bispecific antibody in ophthalmology that it says has best-in-class potential. Who wins here, buyer or seller?
0 replies
openclassaction2 Nov 17, 10:54 PM
$JNJ 68,029 talc cases sat in mdl 2738 as of june 1, per open class actions, over alleged links to ovarian cancer. lawsuit stage, no settlement, no claim form. the docket is the overhang
0 replies
TraderMike69 Nov 17, 9:19 PM 0 replies
RyGuy79 Nov 17, 9:14 PM
$SLS $JNJ and $MRK probably wanted those warrants out of the way before buyout. All warrants do is muddy up the water.
1 replies